

**ГАСТРОЭНТЕРОЛОГИИ**

**И**

**НУТРИЦИОЛОГИИ**



**БЕЛМАПО**

( /IPP)

:

I :

Ø ( 1978 ., 1989 . - .) -

Ø ( , ).

Ø ( , ).

II :

Ø ( , )

III :

Ø ( ) - S-

2001 .

?


per os

( - )


( . . - 1000 ' )

( )

+ / + -




# PPI



Adapted from Sachs G, et al. *Annu Rev Pharmacol Toxicol*. 1995;35:277-305.

# PPI



Adapted from Sachs G, et al. *Annu Rev Pharmacol Toxicol.* 1995;35:277-305.

' » ( UC),

∴

«

»

«


»

in vivo

AUC



(in vitro)



7-8

in vivo:

>4

16 (

- 40 / - 50%
- 30 / - 5%,
- 40 / - 10%,
- 20 / - 25%.



Ø

Ø

Ø

Ø

Ø

Ø


Ø

).

?

?

*Helicobacter pylori*






2<sup>-</sup>



-

# Meta-analysis





\* $P < .001$  vs H2RAs.

Chiba N et al. *Gastroenterology*. 1997;112:1798-1810.

# Helicobacter pylori

- 
- 
- 
- $H$  in vitro ( ) > ( 16 ) > ( 10 ) > ( 4 ) : ( 16 ) > ( 100 ) > ( 4 ) >  $2^{-}$  ( 100 ) .
- **in vivo** ( - 2% - 5% ).
- **Hp** :
- ( ( ) H , + ) .
- 





2<sup>-</sup>

- : +11% - 4 ( - , n=3504),  
- : +10% - 4 ( - ).

2<sup>-</sup>

40 /

- 20

/c .

= = =

( ).

- $2^{-}$
- $4$
- $4$
- $(, n = 347),$
- $(, n = 1500).$

- $10\% - 15\%.$

- $8$
- $40 /$
- $> 1 : 83\%$





- $= = = -$

- $($
- $).$



1970 - 1999 .).





	CYP2C19	CYP3A4	II ( )	CYP450
	++++	++	-	-
	+++	+++	-	-
	++++	++	+++++	-
	+	+	-	++++
	+/-	+/-	-	++++

# CYP2C19

		-	-
	<b>75%</b>	<b>22%</b>	<b>3%</b>
	<b>66%</b>	<b>31%</b>	<b>3%</b>
	-	-	<b>15%</b>
	-	-	<b>30%</b>



( )



/ /

/

/

/

/ /

/

/

/

/

/

. 12,

/

/

/

/

/

/

/



/

/

/


/

/

.



( )



• FDA:

- 
- 

«

-2000 (

»

3).

•

2<sup>-</sup>

in vivo:

> = = = .

: = = = > 2<sup>-</sup>

CYP2C19 ( . .

) - .

:

4%

2%

